Physician profile
Diana Smith
NPI 1396121497
$4,150.97
in general payments reported to CMS, 2019-2025
31 companies · $804 in 2025
The $804 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $813 · 2022: $1,049 · 2023: $817 · 2024: $668 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,289.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $790.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $438.64 | 2021-2025 | Cuvitru, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $373.31 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $348.47 | 2021-2024 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $280.03 | 2021-2025 | |
| Abbvie INC. | $197.59 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.04 | 2021-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.74 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $161.67 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $152.74 | 2025 | |
| Pfizer INC. | $151.22 | 2021-2025 | |
| Lilly USA, LLC | $124.23 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Amgen INC. | $117.82 | 2021-2024 | Otezla, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $106.86 | 2021-2023 | Verquvo |
| Exact Sciences Corporation | $62.17 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $60.50 | 2023-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $50.70 | 2022 | |
| Dexcom, INC. | $38.72 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $36.98 | 2022-2023 | Quviviq |
| Abbott Laboratories | $36.44 | 2021-2023 | Freestyle Libre 3 |
| Eisai INC. | $35.61 | 2021-2022 | |
| Corcept Therapeutics | $31.77 | 2021 | |
| Aimmune Therapeutics, INC. | $28.12 | 2021 | |
| Esperion Therapeutics, INC. | $27.17 | 2021-2025 | Nexletol |
| Hikma Pharmaceuticals USA | $22.76 | 2025 | Ryaltris |
| Almatica Pharma LLC | $19.23 | 2023 | Loreev Xr |
| Allergan, INC. | $18.63 | 2021 | |
| Sanofi Pasteur INC. | $16.61 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.96 | 2023 | Livalo |
| Ibsa Pharma INC. | $15.89 | 2023 | Tirosint, Licart |
| Phathom Pharmaceuticals, INC. | $12.15 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.